CoChat
Sign Up
Cited by 48Multiple Sclerosis Research StudiesAdvanced Neuroimaging Techniques and ApplicationsGlaucoma and retinal disorders

Optic nerve diffusion tensor imaging after acute optic neuritis predicts axonal and visual outcomes

Open access
van der Walt, Anneke, Kolbe, Scott C., Wang, Yejun E., Klistorner, Alexander, Shuey, Neil, Ahmadi, Gelareh, Paine, Mark, Marriott, Mark +4 more·2013·PLoS ONE
DOI 10.1371/journal.pone.0083825PMC PMC3873392
Open this paper in CoChat — free accountOpen PDF

Abstract

BACKGROUND: Early markers of axonal and clinical outcomes are required for early phase testing of putative neuroprotective therapies for multiple sclerosis (MS). OBJECTIVES: To assess whether early measurement of diffusion tensor imaging (DTI) parameters (axial and radial diffusivity) within the optic nerve during and after acute demyelinating optic neuritis (ON) could predict axonal (retinal nerve fibre layer thinning and multi-focal visual evoked potential amplitude reduction) or clinical (visual acuity and visual field loss) outcomes at 6 or 12 months. METHODS: Thirty-seven patients presenting with acute, unilateral ON were studied at baseline, one, three, six and 12 months using optic nerve DTI, clinical and paraclinical markers of axonal injury and clinical visual dysfunction. RESULTS: Affected nerve axial diffusivity (AD) was reduced at baseline, 1 and 3 months. Reduced 1-month AD correlated with retinal nerve fibre layer (RNFL) thinning at 6 (R=0.38, p=0.04) and 12 months (R=0.437, p=0.008) and VEP amplitude loss at 6 (R=0.414, p=0.019) and 12 months (R=0.484, p=0.003). AD reduction at three months correlated with high contrast visual acuity at 6 (ρ = -0.519, p = 0.001) and 12 months (ρ = -0.414, p=0.011). The time-course for AD reduction for each patient was modelled using a quadratic regression. AD normalised after a median of 18 weeks and longer normalisation times were associated with more pronounced RNFL thinning and mfVEP amplitude loss at 12 months. Affected nerve radial diffusivity (RD) was unchanged until three months, after which time it remained elevated. CONCLUSIONS: These results demonstrate that AD reduces during acute ON. One month AD reduction correlates with the extent of axonal loss and persistent AD reduction at 3 months predicts poorer visual outcomes. This suggests that acute ON therapies that normalise optic nerve AD by 3 months could also promote axon survival and improve visual outcomes.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0083825

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Previous studies have shown that EpoD and NAP can reduce p-tau pathology in AD model mice over several months of treatment.

    “Additionally, previous studies utilizing EpoD as well as microtubule-stabilizing peptide NAP have both shown ability to reduce p-tau pathology in AD model mice over several months of treatment 31,66,67”

    From Amyloid-beta induced retrograde axonal degeneration in a mouse tauopathy model (2019) · cites this paper as [66]

    The Discussion (page unavailable) concerns optic-nerve diffusion imaging after acute optic neuritis; its “AD” refers to axial diffusivity, not Alzheimer’s disease. Searches for EpoD, NAP, phosphorylated tau, and Alzheimer’s model mice found no passage addressing the claimed treatment effects. (LLM, conf=0.76)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 40 · Cited by 48

Research works printed but not linked: 35

  1. [1]Barkhof F (1999) MRI in multiple sclerosis: correlation with expanded disability status scale (EDSS). Mult Scler 5: 283– 286. doi: 10.1177/135245859900500415. PubMed: 10467389. 10467389 · DOI
  2. [2]Rocca MA, Hickman SJ, Bö L, Agosta F, Miller DH et al. (2005) Imaging the optic nerve in multiple sclerosis. Mult Scler 11: 537– 541. doi: 10.1191/1352458505ms1213oa. PubMed: 16193891. 16193891 · DOI
  3. [3]Van der Walt A, Butzkueven H, Kolbe S, Marriott M, Alexandrou E et al. (2010) Neuroprotection in multiple sclerosis: a therapeutic challenge for the next decade. Pharmacol Ther 126: 82– 93. doi: 10.1016/j.pharmthera.2010.01.006. PubMed: 20122960. 20122960 · DOI
  4. [4]Frohman EM, Costello F, Stüve O, Calabresi P, Miller DH et al. (2008) Modeling axonal degeneration within the anterior visual system: implications for demonstrating neuroprotection in multiple sclerosis. Arch Neurol 65: 26– 35. doi: 10.1001/archneurol.2007.10. PubMed: 18195137. 18195137 · DOI
  5. [5]Klistorner A, Graham S, Fraser C, Garrick R, Nguyen T et al. (2007) Electrophysiological evidence for heterogeneity of lesions in optic neuritis. Invest Ophthalmol Vis Sci 48: 4549– 4556. Available: http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=17898277&retmode=ref&cmd=prlinks. doi: 10.1167/iovs.07-0381. PubMed: 17898277. 17898277 · DOI
  6. [6]Fraser CL, Klistorner A, Graham SL, Garrick R, Billson FA et al. (2006) Multifocal visual evoked potential analysis of inflammatory or demyelinating optic neuritis. Ophthalmology 113: 323– 323. PubMed: 16406544. 16406544
  7. [7]Klistorner A, Arvind H, Nguyen T, Garrick R, Paine M et al. (2008) Axonal loss and myelin in early ON loss in postacute optic neuritis. Ann Neurol 64: 325– 331. doi: 10.1002/ana.21474. PubMed: 18825673. 18825673 · DOI
  8. [8]Costello F, Hodge W, Pan YI, Eggenberger E, Coupland S et al. (2008) Tracking retinal nerve fiber layer loss after optic neuritis: a prospective study using optical coherence tomography. Mult Scler 14: 893– 905. doi: 10.1177/1352458508091367. PubMed: 18573837. 18573837 · DOI
  9. [9]Costello F, Hodge W, Pan YI, Freedman M, DeMeulemeester C (2009) Differences in retinal nerve fiber layer atrophy between multiple sclerosis subtypes. J Neurol Sci 281: 74– 79. doi: 10.1016/j.jns.2009.02.354. PubMed: 19303605. 19303605 · DOI
  10. [10]Henderson APD, Trip SA, Schlottmann PG, Altmann DR, Garway-Heath DF et al. (2008) An investigation of the retinal nerve fibre layer in progressive multiple sclerosis using optical coherence tomography. Brain 131: 277– 287. doi: 10.1093/brain/awm285. PubMed: 18056739. 18056739 · DOI
  11. [11]Naismith RT, Xu J, Tutlam NT, Lancia S, Trinkaus K et al. (2012) Diffusion Tensor Imaging in Acute Optic Neuropathies: Predictor of Clinical Outcomes. Arch Neurol 69: 65– 71. doi: 10.1001/archneurol.2011.243. PubMed: 21911658. 21911658 PMC3489058 · DOI
  12. [12]Naismith RT, Xu J, Tutlam NT, Snyder A, Benzinger T et al. (2009) Disability in optic neuritis correlates with diffusion tensor-derived directional diffusivities. Neurology 72: 589– 594. Available: doi:10.1212/01.wnl.0000335766.22758.cd. Available online at: doi:10.1212/01.wnl.0000335766.22758.cd. PubMed: 19073948. 19073948 PMC2672917 · DOI · Paper page
  13. [13]Song S-K, Sun S-W, Ju W-K, Lin S-J, Cross AH et al. (2003) Diffusion tensor imaging detects and differentiates axon and myelin degeneration in mouse optic nerve after retinal ischemia. NeuroImage 20: 1714– 1722. doi: 10.1016/j.neuroimage.2003.07.005. PubMed: 14642481. 14642481 · DOI · Paper page
  14. [14]Mac Donald CL, Dikranian K, Song S-K, Bayly PV, Holtzman DM et al. (2007) Detection of traumatic axonal injury with diffusion tensor imaging in a mouse model of traumatic brain injury. Exp Neurol 205: 116– 131. doi: 10.1016/j.expneurol.2007.01.035. PubMed: 17368446. 17368446 PMC1995439 · DOI
  15. [15]O'riordan J, Thompson A, Kingsley D (1998) The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. Brain. 9549525
  16. [16]Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA et al. (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69: 292– 302. doi: 10.1002/ana.22366. PubMed: 21387374. 21387374 PMC3084507 · DOI · Paper page
  17. [18]Balcer LJ, Baier ML, Cohen JA, Kooijmans MF, Sandrock AW et al. (2003) Contrast letter acuity as a visual component for the Multiple Sclerosis Functional Composite. Neurology 61: 1367– 1373. doi: 10.1212/01.WNL.0000094315.19931.90. PubMed: 14638957. 14638957 · DOI
  18. [19]Baier ML, Cutter GR, Rudick RA, Miller D, Cohen JA et al. (2005) Low-contrast letter acuity testing captures visual dysfunction in patients with multiple sclerosis. Neurology 64: 992– 995. doi: 10.1212/01.WNL.0000154521.40686.63. PubMed: 15781814. 15781814 · DOI
  19. [21]Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 33: 1444– 1444. doi: 10.1212/WNL.33.11.1444. PubMed: 6685237. 6685237 · DOI · Paper page
  20. [22]Kolbe S, Chapman C, Nguyen T, Bajraszewski C, Johnston L et al. (2009) Optic nerve diffusion changes and atrophy jointly predict visual dysfunction after optic neuritis. NeuroImage 45: 679– 686. doi: 10.1016/j.neuroimage.2008.12.047. PubMed: 19162205. 19162205 · DOI
  21. [24]Wu Q, Butzkueven H, Gresle M, Kirchhoff F (2007) MR diffusion changes correlate with ultra-structurally defined axonal degeneration in murine optic nerve. NeuroImage 37: 1138– 1147. doi: 10.1016/j.neuroimage.2007.06.029. PubMed: 17689104. 17689104 · DOI
  22. [26]Hickman SJ, Wheeler-Kingshott CAM, Jones SJ, Miszkiel KA, Barker GJ et al. (2005) Optic nerve diffusion measurement from diffusion-weighted imaging in optic neuritis. AJNR Am J Neuroradiol 26: 951– 956. PubMed: 15814951. 15814951 PMC7977095
  23. [27]Halliday AM, McDonald WI, Mushin J (1972) Delayed visual evoked response in optic neuritis. Lancet 1: 982– 985. PubMed: 4112367. 4112367
  24. [28]Hayreh SS, Zimmerman MB (2008) Nonarteritic anterior ischemic optic neuropathy: natural history of visual outcome. Ophthalmology 115: 298–305. e2 doi: 10.1016/j.ophtha.2007.05.027. PMC2782939 17698200 · DOI · Paper page
  25. [29]La Cruz De J (2006) Clinical profile of simultaneous bilateral optic neuritis in adults. Br J Ophthalmol 90: 551– 554. doi: 10.1136/bjo.2005.085399. PubMed: 16622084. Available online at: 10.1136/bjo.2005.085399 Available online at: PubMed: 16622084 16622084 PMC1857074 · DOI
  26. [30]Fu Q-L, Hu B, Wu W, Pepinsky RB, Mi S et al. (2008) Blocking LINGO-1 function promotes retinal ganglion cell survival following ocular hypertension and optic nerve transection. Invest Ophthalmol Vis Sci 49: 975– 985. doi: 10.1167/iovs.07-1199. PubMed: 18326721. 18326721 · DOI
  27. [31]Mi S, Miller RH, Lee X, Scott ML, Shulag-Morskaya S et al. (2005) LINGO-1 negatively regulates myelination by oligodendrocytes. Nat Neurosci 8: 745– 751. doi: 10.1038/nn1460. PubMed: 15895088. 15895088 · DOI
  28. [32]Sühs K-W, Hein K, Sättler MB, Görlitz A, Ciupka C et al. (2012) A randomized, double-blind, phase 2 study of erythropoietin in optic neuritis. Ann Neurol 72: 199– 210. doi: 10.1002/ana.23573. PubMed: 22926853. 22926853 · DOI
  29. [33]Cleary PA, Beck R, Bourque L, Backlund J, Miskala P (1997) Visual symptoms after optic neuritis. Results from the Optic Neuritis Treatment. Trial - Journal of Neuro-Ophthalmology: the Official Journal of the North American Neuro-Ophthalmology Society 17: 18– 23. 9093956
  30. [34]Beck RW, Gal RL, Bhatti MT, Brodsky MC, Buckley EG et al. (2004) Visual function more than 10 years after optic neuritis: experience of the optic neuritis treatment trial. Am J Ophthalmol 137: 77– 83. doi: 10.1016/S0002-9394(03)00862-6. PubMed: 14700647. 14700647 · DOI
  31. [35]Kolbe SC, Marriott M, van der Walt A, Fielding J, Klistorner A et al. (2012) Diffusion Tensor Imaging Correlates of Visual Impairment in Multiple Sclerosis and Chronic Optic Neuritis. Invest Ophthalmol Vis Sci 53: 825– 832. doi: 10.1167/iovs.11-8864. PubMed: 22247457. 22247457 · DOI
  32. [36]Talman LS, Bisker ER, Sackel DJ, Long DA, Galetta KM et al. (2010) Longitudinal study of vision and retinal nerve fiber layer thickness in multiple sclerosis. Ann Neurol 67: 749– 760. doi: 10.1002/ana.22005. PubMed: 20517936. 20517936 PMC2901775 · DOI
  33. [37]Balcer LJ, Galetta SL, Calabresi PA, Confavreux C, Giovannoni G et al. (2007) Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. Neurology 68: 1299– 1304. doi: 10.1212/01.wnl.0000259521.14704.a8. PubMed: 17438220. 17438220 · DOI
  34. [38]Jenkins TM, Toosy AT, Ciccarelli O, Miszkiel KA, Wheeler-Kingshott CA et al. (2010) Neuroplasticity predicts outcome of optic neuritis independent of tissue damage. Ann Neurol 67: 99– 113. doi: 10.1002/ana.21823. PubMed: 20186956. 20186956 · DOI
  35. [39]Wang Y, Van der Walt A, Paine M, Klistorner A, Butzkueven H et al. (2012) Optic nerve magnetisation transfer ratio after acute optic neuritis predicts axonal and visual outcomes. PLOS ONE 7: e52291. doi: 10.1371/journal.pone.0052291. PubMed: 23272235. 23272235 PMC3525585 · DOI

Authors
van der Walt, A., Kolbe, S. C., Wang, Y. E., Klistorner, A., Shuey, N., Ahmadi, G., Paine, M., Marriott, M., Mitchell, P., Egan, G. F., Butzkueven, H., & Kilpatrick, T. J.
Affiliations
  • The University of Melbourne (AU)
  • The University of Sydney (AU)
  • The Royal Victorian Eye & Ear Hospital (AU)
  • The Royal Melbourne Hospital (AU)
  • Monash University (AU)
ORCID
Venue
PLoS ONE
Publisher
Public Library of Science (PLoS)
Published
2013-12-26
Volume
8
Issue
12
Pages
e83825
ISSN
1932-6203 (ISSN-L)
DOI
10.1371/journal.pone.0083825
PMC
PMC3873392
OpenAlex
W2011888439
Cited by
48
References
40
Citations by year
2024: 3 · 2023: 1 · 2022: 2 · 2021: 3 · 2020: 4 · 2019: 2 · 2018: 7 · 2017: 4 · 2016: 8 · 2015: 7 · 2014: 7
FWCI
5.50
Type
journal article
Language
en
Open access
Licence
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Monash University Research Portal (Monash University) (submittedVersion, cc-by)
  • Minerva Access (University of Melbourne) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Multiple Sclerosis Society (RG4211A4/2)
  • GlaxoSmithKline
  • Biogen
  • Medical Research Council
  • National Health and Medical Research Council
Topics
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Multiple Sclerosis Research Studies
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Advanced Neuroimaging Techniques and Applications
  • Health Sciences › Medicine › Ophthalmology › Glaucoma and retinal disorders
Keywords
optic neuritis, diffusion tensor imaging, optic nerve, axial diffusivity, radial diffusivity, axonal injury, retinal nerve fiber layer thinning, visual acuity, visual field defects, multiple sclerosis, neuroprotection
MeSH terms
Adolescent, Adult, Axons, Female, Follow-Up Studies, Humans, Male, Middle Aged, Multiple Sclerosis, Optic Nerve, Optic Neuritis, Prognosis, Risk, Visual Acuity, Visual Fields, Visual Perception, Reproducibility of Results, Young Adult, Diffusion Tensor Imaging

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review